Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.81 Million CHF | 1576.85% |
| 2022 | 108 Thousand CHF | -74.77% |
| 2021 | 428 Thousand CHF | -11.02% |
| 2020 | 481 Thousand CHF | -92.99% |
| 2019 | 6.85 Million CHF | -26.1% |
| 2018 | 9.28 Million CHF | -8.52% |
| 2017 | 10.14 Million CHF | 32.19% |
| 2016 | 7.67 Million CHF | 123.07% |
| 2015 | 3.44 Million CHF | 664.1% |
| 2014 | -610 Thousand CHF | 0.0% |
| 2013 | - CHF | -100.0% |
| 2012 | 27 Thousand CHF | -98.87% |
| 2011 | 2.39 Million CHF | -22.42% |
| 2010 | 3.08 Million CHF | -5.95% |
| 2009 | 3.27 Million CHF | -19.33% |
| 2008 | 4.06 Million CHF | 595.55% |
| 2007 | 584 Thousand CHF | 26.41% |
| 2006 | 462 Thousand CHF | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 6.02 Million CHF | 232.63% |
| 2024 Q2 | 6.02 Million CHF | 0.0% |
| 2023 Q4 | 1.81 Million CHF | 0.0% |
| 2023 FY | 1.81 Million CHF | 1576.85% |
| 2023 Q1 | - CHF | -100.0% |
| 2023 Q3 | 1.81 Million CHF | -72.77% |
| 2023 Q2 | 6.65 Million CHF | 0.0% |
| 2022 Q3 | 108 Thousand CHF | -49.3% |
| 2022 FY | 108 Thousand CHF | -74.77% |
| 2022 Q4 | 108 Thousand CHF | 0.0% |
| 2022 Q1 | 213 Thousand CHF | -50.23% |
| 2022 Q2 | 213 Thousand CHF | 0.0% |
| 2021 Q2 | 437 Thousand CHF | 0.0% |
| 2021 FY | 428 Thousand CHF | -11.02% |
| 2021 Q4 | 428 Thousand CHF | 0.0% |
| 2021 Q3 | 428 Thousand CHF | -2.06% |
| 2021 Q1 | 437 Thousand CHF | -9.15% |
| 2020 Q2 | 6.9 Million CHF | 0.0% |
| 2020 Q1 | 6.9 Million CHF | 0.69% |
| 2020 FY | 481 Thousand CHF | -92.99% |
| 2020 Q4 | 481 Thousand CHF | 0.0% |
| 2020 Q3 | 481 Thousand CHF | -93.04% |
| 2019 Q2 | 9.02 Million CHF | 0.0% |
| 2019 Q3 | 6.85 Million CHF | -24.03% |
| 2019 FY | 6.85 Million CHF | -26.1% |
| 2019 Q4 | 6.85 Million CHF | 0.0% |
| 2019 Q1 | 9.02 Million CHF | -2.73% |
| 2018 Q2 | 9.44 Million CHF | 0.0% |
| 2018 Q1 | 9.44 Million CHF | -6.94% |
| 2018 Q4 | 9.28 Million CHF | -0.4% |
| 2018 Q3 | 9.31 Million CHF | -1.31% |
| 2018 FY | 9.28 Million CHF | -8.52% |
| 2017 Q2 | 9.52 Million CHF | 0.0% |
| 2017 Q1 | 9.52 Million CHF | 24.05% |
| 2017 Q4 | 10.14 Million CHF | 0.0% |
| 2017 FY | 10.14 Million CHF | 32.19% |
| 2016 Q1 | 5.79 Million CHF | 68.5% |
| 2016 Q3 | 7.67 Million CHF | 32.39% |
| 2016 Q4 | 7.67 Million CHF | 0.0% |
| 2016 Q2 | 5.79 Million CHF | 0.0% |
| 2016 FY | 7.67 Million CHF | 123.07% |
| 2015 FY | 3.44 Million CHF | 664.1% |
| 2015 Q1 | 2.78 Million CHF | 556.89% |
| 2015 Q2 | 2.78 Million CHF | 0.0% |
| 2015 Q3 | 3.44 Million CHF | 23.47% |
| 2015 Q4 | 3.44 Million CHF | 0.0% |
| 2014 Q3 | - CHF | 100.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 FY | -610 Thousand CHF | 0.0% |
| 2014 Q4 | -610 Thousand CHF | 0.0% |
| 2014 Q2 | -312 Thousand CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 100.0% |
| 2013 Q2 | -249 Thousand CHF | 0.0% |
| 2013 Q1 | - CHF | -100.0% |
| 2013 FY | - CHF | -100.0% |
| 2012 Q2 | 2.41 Million CHF | 0.0% |
| 2012 Q3 | 27 Thousand CHF | -98.88% |
| 2012 Q4 | 27 Thousand CHF | 0.0% |
| 2012 FY | 27 Thousand CHF | -98.87% |
| 2011 Q4 | 2.39 Million CHF | 0.0% |
| 2011 FY | 2.39 Million CHF | -22.42% |
| 2011 Q2 | 3.02 Million CHF | 0.0% |
| 2010 FY | 3.08 Million CHF | -5.95% |
| 2010 Q2 | 3.13 Million CHF | 0.0% |
| 2010 Q4 | 3.08 Million CHF | 0.0% |
| 2009 FY | 3.27 Million CHF | -19.33% |
| 2009 Q4 | 3.27 Million CHF | 0.0% |
| 2008 FY | 4.06 Million CHF | 595.55% |
| 2007 FY | 584 Thousand CHF | 26.41% |
| 2006 FY | 462 Thousand CHF | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Addex Therapeutics Ltd | - CHF | -Infinity% |
| BB Biotech AG | -2.63 Billion CHF | 100.069% |
| Basilea Pharmaceutica AG | 26.41 Million CHF | 93.143% |
| Evolva Holding SA | - CHF | -Infinity% |
| Idorsia Ltd | 59.14 Million CHF | 96.938% |
| Kuros Biosciences AG | 4.85 Million CHF | 62.706% |
| Molecular Partners AG | - CHF | -Infinity% |
| Relief Therapeutics Holding AG | 557 Thousand CHF | -225.135% |